ZETA SURGICAL

Name

ZETA SURGICAL

Legal name

Zeta Surgical, Inc.

Website

https://zetasurgical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

ZETA SURGICAL is a Boston-based medical technology company that develops AI-powered, frameless neuronavigation systems for neurosurgery and transcranial magnetic stimulation, sold to hospitals, outpatient clinics, and ambulatory surgical centers.

Ownership category

akta.pro rank

Product category

Neurosurgical Navigation Systems

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)

Keywords

• Neurosurgical navigation systems
• Image-guided surgery
• Transcranial magnetic stimulation
• Medical navigation robotics
• Frameless neuronavigation

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Navigation System Hardware Sales: Sale of Zeta Cranial Navigation System and Zeta TMS Navigation System as capital medical equipment to hospitals, surgical centers, and outpatient clinics. The systems are FDA-cleared and commercially available in the United States.
2. Navigation System Service and Support: Ongoing maintenance, support, and potentially software updates for deployed navigation systems in clinical settings.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

ZETA SURGICAL develops and sells FDA-cleared, AI-powered neuronavigation systems for neurosurgical procedures and transcranial magnetic stimulation (TMS). Its flagship products are the Zeta Cranial Navigation System and the Zeta TMS Navigation System, both powered by the proprietary RealTrack computer-vision platform that delivers sub-millimetric, markerless, frameless image guidance deployable in operating rooms, emergency settings, and outpatient clinics.

Product overview

ZETA SURGICAL offers a platform of AI-powered neuronavigation products for neurosurgery and neuromodulation. The core offerings include the Zeta Navigation System (for neurosurgical procedures) and the Zeta TMS Navigation System (for transcranial magnetic stimulation), both using the proprietary RealTrack™ computer vision technology for frameless, real-time guidance. These are complemented by navigated instruments Zeta Stylet and Zeta Bolt. The platform enables sub-millimetric accuracy without skull fixation or general anesthesia, deployable across operating rooms, emergency settings, and outpatient clinics.

Differentiator

Problem solved

Functional benefit

Products and services

• Zeta Navigation System FDA-cleared computer-assisted, real-time image guidance system for spatial positioning and orientation of neurosurgical instruments. Uses computer vision and AI to align preoperative CT or MRI scans with patient anatomy, providing sub-millimeter navigation at virtually any point-of-care for external ventricular drain placement, brain biopsy, tumor resection, and trigeminal rhizotomies.
• Zeta TMS Navigation System FDA-cleared AI-powered navigation system for transcranial magnetic stimulation providing real-time, markerless image guidance with sub-millimetric accuracy. Uses RealTrack technology to align patient MRI or CT imaging with facial anatomy and continuously track TMS coil positioning across treatment sessions for major depressive disorder and other neurological conditions.
• Zeta Stylet FDA-cleared navigated instrument that integrates with the Zeta Navigation System for neurosurgical procedures including external ventricular drain placement, brain biopsy, and shunt procedures.
• Zeta Bolt FDA-cleared navigated instrument that integrates with the Zeta Navigation System providing navigated guidance for catheter placements, brain biopsies, and trigeminal rhizotomies.

Quantifiable outcome

• 100% ideal catheter placement vs 32% freehand for EVD procedures
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered flagship, core and minor.

• HOPE Therapeutics (NRx Pharmaceuticals subsidiary)flagshipStrategic or Co-development Partner · 26 May 2026First commercial deployment of Zeta TMS Navigation System at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida. The partnership supports outpatient TMS therapy for major depressive disorder and represents ZETA's transition from R&D to commercial operations.
• Big 10 Neurosurgical ConsortiumcoreStrategic or Co-development Partner · 1 May 2026Large-scale commercial pilot program planned for 2026 with the Big 10 Neurosurgical Consortium for Zeta Navigation System deployment across member institutions.
• NRx Defense SystemscoreStrategic or Co-development Partner · 15 April 2026Partnership to develop robotic-enabled Transcranial Magnetic Stimulation combined with neuroplastic therapy for military and first responder applications. ZETA provides AI-powered neuronavigation platform; NRx Defense Systems focuses on D-Cycloserine (NRX-101) combined with TMS. Prototype unveiling planned for June 2026 at Clinical TMS Society meeting.
• University of CambridgeminorStrategic or Co-development Partner · 13 October 2025Collaborative study with University of Cambridge and Harvard Medical School demonstrating sub-millimeter translational and sub-degree angular precision for navigated TMS.
• Imperial College LondonminorStrategic or Co-development Partner · 1 November 2024Research collaboration on SCOUT (Skull-Corrected Optimization for Ultrasound Transducers) project for skull-corrected ultrasound imaging.
• Singapore General Hospital and Tan Tock Seng HospitalcoreStrategic or Co-development Partner · 7 June 2024Multi-center clinical trial sites for first multicenter clinical trial using Zeta Cranial Navigation System. Fifteen patients successfully cannulated in single attempt with no adverse events.
• National Neuroscience Institute, SingaporecoreStrategic or Co-development Partner · 1 January 2024First-in-human clinical trial site for EVD procedures using ZETA navigation system. Successful trial demonstrated 100% ideal catheter placement and 0% adverse events across all cases.
• Harvard Medical School (Brigham and Women's Hospital, Massachusetts General Hospital)coreStrategic or Co-development PartnerPrimary research and clinical development partnership. Dr. William Gormley serves as Co-Founder and Director of Neurosurgical Innovation at Harvard Medical School's Brigham and Women's Hospital. Multiple joint publications and clinical studies.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• 7D Surgical: 7D Surgical (now part of Proprio Vision) develops machine-vision surgical navigation systems for spine and cranial procedures. It is a direct competitor with a comparable value proposition of markerless, fast-setup image guidance in neurosurgery and spine.
• Brainlab: Brainlab is a direct competitor in image-guided surgical navigation for neurosurgery and other specialties. Its Curve and Kick navigation platforms compete directly with the Zeta Navigation System in hospital neurosurgery departments and address overlapping use cases including cranial and spine procedures.
• Synaptive Medical: Synaptive Medical sells image-guided neurosurgical platforms (e.g., Modus V, BrightMatter) directly competing with ZETA's navigation system in cranial procedures. Both companies target academic and community neurosurgery departments with AI/computer-vision-enabled navigation.
• Neuronetics: Neuronetics sells NeuroStar TMS systems for treatment-resistant depression and adjacent indications. As ZETA's TMS Navigation System is sold alongside TMS treatment delivery to psychiatric and neurology clinics, Neuronetics is a directly adjacent peer with overlapping customers and complementary (rather than competing) positioning.
• BrainsWay: BrainsWay develops deep TMS systems for depression, OCD, and other psychiatric conditions, competing in the same outpatient psychiatric clinic channel as ZETA's TMS navigation deployments. Its clinical evidence base and reimbursement infrastructure shape the same customer conversations ZETA enters.

Broad incumbents

• Medtronic (StealthStation): Medtronic's StealthStation is the entrenched leader in surgical navigation with a large installed base across neurosurgery and spine ORs. It competes with ZETA across the same neurosurgical use cases but as part of a much broader neuromodulation and cranial portfolio.
• Stryker (Navigation): Stryker offers surgical navigation systems (acquired with MAKO and other platforms) used in neurosurgery and other OR settings. It is a broad incumbent competing with ZETA in the same hospital neurosurgery procurement cycles but with a much larger capital equipment portfolio.

Emerging players

• Surgical Theater: Surgical Theater provides VR-based surgical planning and visualization tools for neurosurgery that complement or compete with image-guidance workflows. It is an emerging player with overlapping neurosurgical customers and adjacent positioning in pre-operative planning.
• Soterix Medical: Soterix Medical develops non-invasive brain stimulation and neuromodulation devices (including TMS and tDCS systems) for research and clinical use. It is an emerging peer competing in the same brain-circuit therapeutics market served by ZETA's TMS navigation.
• Viz.ai: Viz.ai applies AI imaging triage to acute neurological care (stroke, etc.), operating adjacent to ZETA in AI-enabled neuro workflows. While not a navigation competitor, it is led by a former Viz.AI Global VP (Dr. Aimee Degaetano) who now advises ZETA, signaling ecosystem overlap.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZETA SURGICAL